Heart Sciences’ Directors Flood into Shares as Merger With Fortitude Mining Gains Momentum

Insider Activity Signals Confidence Amid a Major Merger

On June 22, 2026, Andrew Simpson, a long‑time director and shareholder of HEARTSCIENCES INC, executed a sizeable purchase of 425,000 shares, raising his holdings to roughly 499,000 shares. The transaction, executed at $2.63 per share, came as part of the company’s 2023 Equity Incentive Plan and is tied directly to the pending merger with Fortitude Mining Holdings. The deal, announced earlier this year, will merge HEARTSCIENCES into the digital‑currency mining group, with HEARTSCIENCES shareholders retaining a minority stake in the new entity. Simpson’s acquisition—made in a context where the stock is hovering near its 52‑week low—suggests that senior management remains optimistic about the strategic fit and long‑term value that the merger is expected to generate.

A Broader Insider Buy‑Wave

Simpson’s trade is not an isolated event. In the first quarter of 2026, several other executives—David R. Wells, Bruce Bent, Mark T. Hilz, Brian Szymczak, and Danielle Watson—reported purchases of restricted stock units, all at zero transaction price as part of their vesting schedules. The timing of these transactions aligns with the merger’s closing milestones, indicating that the leadership team is aligning its personal interests with those of shareholders. The concentration of insider buying, especially in a company that has experienced a steep annual decline (-31.51%) and a low price‑to‑earnings ratio of -0.48, is a noteworthy signal that the board believes the deal will unlock value and improve earnings prospects.

Implications for Investors

For investors, the insider activity can be read as a bullish endorsement of the merger’s prospects. The board’s decision to grant a retention bonus to Simpson—contingent on the closing of the transaction—reinforces the narrative that HEARTSCIENCES’ existing leadership will play a pivotal role in the integrated entity. However, the stock’s current trading price ($2.75) remains far below its 52‑week high of $6.47, and the company’s valuation remains modest at a market cap of just $9 M. Potential upside will largely depend on the successful regulatory approval of the merger and the ability of the combined company to generate synergies between medical device operations and mining capital markets. Until those hurdles are cleared, the stock’s volatility—highlighted by a 44.51% weekly gain—could continue to challenge long‑term investors.

Strategic Outlook

The merger represents a strategic pivot for HEARTSCIENCES: from a niche medical‑device firm to a component of a larger, diversified technology and mining group. By retaining a minority interest, HEARTSCIENCES shareholders preserve a stake in the original business while gaining exposure to the growth potential of digital‑currency mining. If the integration delivers on its promises, the combined entity could command higher valuations, improve liquidity, and broaden its investor base. For now, the insider buying activity, coupled with the board’s retention incentives, signals confidence—yet investors will need to monitor regulatory approvals, integration timelines, and the company’s ability to harmonize two distinct operational models.